South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
